4 March 2024

Important Advance Notice of Product Discontinuation
PenMix® 30, PenMix® 50 and Mixtard® 30, 30 September 2024

Dear Healthcare Professional,

The introduction of newer diabetes therapies has changed the diabetes paradigm across the world. In New Zealand this has resulted in decline in demand for PenMix® 30, PenMix® 50 and Mixtard® 30. Meeting this level of demand is not feasible. As a result, Novo Nordisk New Zealand has informed PHARMAC in Q4 2023 of its decision to discontinue supply of PenMix® 30, PenMix® 50 and Mixtard® 30 from 30 September 2024 onwards.

Brand	Generic	Pharmacode
Mixtard® 30 100 IU/mL vial	Isophane insulin, insulin neutral	797189
PenMix® 30 100 IU/mL cartridge	Isophane insulin, insulin neutral	785733
PenMix® 50 100 IU/mL cartridge	Isophane insulin, insulin neutral	785768

Novo Nordisk is committed to ensuring healthcare professionals have appropriate information, rationale, and time to support a smooth transition to an alternative therapy. The notice of the discontinuation is to encourage healthcare professionals currently prescribing / treating patients with PenMix® 30 or PenMix® 50 or Mixtard® 30 to discuss a safe transition to funded insulin alternatives which can be selected based on your professional assessment and patient profile.

We appreciate that those living with diabetes who are impacted by this discontinuation may have questions or concerns. If you or your patients would like more information, please contact Novo Nordisk Customer Care on 0800 733 737 or email aunrccc@novonordisk.com

Yours sincerely,



Dr Ana Svensson

Senior Director
Clinical, Medical, Regulatory, PV and Quality
Novo Nordisk Oceania